AE Wealth Management LLC purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 1,286 shares of the medical research company’s stock, valued at approximately $211,000.
Several other large investors have also added to or reduced their stakes in AMGN. TrimTabs Asset Management LLC increased its position in shares of Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after buying an additional 288 shares in the last quarter. Alpha Omega Wealth Management LLC increased its position in shares of Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after buying an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. increased its position in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares in the last quarter. Nelson Roberts Investment Advisors LLC purchased a new position in shares of Amgen during the first quarter valued at approximately $121,000. Finally, Signature Estate & Investment Advisors LLC increased its position in shares of Amgen by 13.6% in the first quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock valued at $130,000 after buying an additional 95 shares in the last quarter. Institutional investors own 79.12% of the company’s stock.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at 167.29 on Friday. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $184.21. The company has a market capitalization of $122.07 billion, a P/E ratio of 15.24 and a beta of 1.35. The firm has a 50-day moving average of $174.04 and a 200-day moving average of $168.05.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same period in the previous year, the company earned $2.84 earnings per share. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. On average, equities analysts predict that Amgen Inc. will post $12.57 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be issued a dividend of $1.15 per share. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.75%. Amgen’s payout ratio is 41.93%.
A number of analysts have weighed in on the stock. Mizuho set a $195.00 target price on shares of Amgen and gave the stock a “buy” rating in a research note on Saturday, May 6th. UBS AG reaffirmed a “neutral” rating and set a $174.00 target price (down previously from $175.00) on shares of Amgen in a research note on Monday, May 22nd. BMO Capital Markets reaffirmed a “buy” rating and set a $198.00 target price (down previously from $200.00) on shares of Amgen in a research note on Monday, May 22nd. Morgan Stanley boosted their target price on shares of Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 13th. Finally, Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $203.00 target price (up previously from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $186.64.
In other news, SVP Cynthia M. Patton sold 2,922 shares of the business’s stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the transaction, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is owned by insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.